Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
NEW YORK (TheStreet) -- It's time to anoint a new stock to the list of cult classics that seem to defy gravity, Jim Cramer told his Mad Money viewers Monday. That stock is Ambarella (AMBA), the mobile chip maker that has its chips inside every GoPro (GPRO) camera.
What's a cult stock? It's one that trades purely on momentum and not by any traditional valuation metrics. The stocks of Amazon.com (AMZN), Netflix (NFLX), Tesla Motors (TSLA) and most recently Shake Shack (SHAK) are all enshrined in the cult stock hall of fame.
What makes Ambarella so special? For starters the stock is up over 100% for the year, Cramer noted. When the company last reported, revenue soared by 73%, allowing the company to trounce Wall Street estimates. Management also spoke positively about seemingly endless growth from body cameras, aerial drones, cameras in your car and even in your household doorbell.
But Cramer said it's difficult to recommend a stock that's already had such a huge run, even if its earnings may justify the price in a few years. Stocks that go straight up almost always end badly. Sometimes you just need to admit that you missed it, he concluded.
Executive Decision: Kevin Miles
For his "Executive Decision" segment, Cramer sat down with Kevin Miles, president and CEO of Zoe's Kitchen (ZOES), the Mediterranean restaurant chain that's seen its shares up 17% so far in 2015.
Miles said the key to Zoe's success is providing good food that resonates with customers, something they've been doing for the past 20 years. Zoe's offers a menu that's better for you and also very flavorful.
Miles also commented on his company's business intelligence efforts with partner Tableau (DATA). He said they began exploring business intelligence in 2009 and now provide franchisees with data on sales, labor and the overall health of their brand, all of which help for better planning and execution around the country.
When asked about his company's growth plans, Miles said Zoe's is taking a controlled approach, saturating the areas they're in before expanding into new ones.
Cramer and Zoe's remains both a great concept and one that has excellent execution.
"Own, don't trade Apple (AAPL)," Cramer once again reminded his viewers. As Apple, a stock Cramer owns for his charitable trust, Action Alerts PLUS, kicks off its annual Worldwide Developers Conference in San Francisco, there's no better time to add the world's biggest company to your portfolio, he continued.
Apple's developers conference is not meant for you and me, Cramer added. It's designed to get developers from around the world excited about the company's multiple ecosystems for desktop, mobile and now Apple Watch. This is an essential part of keeping a steady stream of new apps flowing to our devices, even if it has little impact on the price of Apple's stock in the short term.
One item from today's keynote that did catch Cramer's ear was the announcement of an Apple Pay system for small businesses, developed by payment processor Square. But beyond that, Cramer said he didn't hear anything that would move the needle for the behemoth that is Apple.
Executive Decision: Marc Casper
In his second "Executive Decision" segment, Cramer sat down with Marc Casper, president and CEO of Thermo Fisher Scientific (TMO), the scientific equipment company and Action Alerts PLUS holding that has become the arms dealer to the life sciences industry, providing everything they need to get the job done. Shares of Thermo Fisher are up just 2% in 2015.
Casper said despite being a global company that derives 50% of its revenue overseas, his company is navigating the global currency landscape very well and still expect to see 4% to 6% revenue growth in 2015 even with the currency pressures.
Casper commented on recent weakness in Japan, noting the Japanese government was late in passing a budget, which put a crimp on spending. That momentum is now rebuilding, he added. Sales in China have also been strong as Thermo Fisher is perfectly aligned with the Chinese government's priorities of health and food safety.
Another key driver for Thermo Fisher is research and innovation. Casper said 20% of revenue stem from products introduced over the past four years and no one spends more than TMO does, $700 million annually on research and development. That's why his company can partner with the earliest-stage biotech company and be its largest supplier all the way through gaining FDA approval.
Finally, when asked about the use of cash, Casper said the company remains committed to putting cash to work through mergers and acquisitions as well as returning cash via buybacks and dividends.
Focus on Drug Distributors
With the Federal Reserve poised to raise interest rates, there's a good chance the U.S. economy will be growing slowly for the foreseeable future. That means investors should be looking for companies that do well in a slow-growth environment, like health care cost containment companies.
Last week, Cramer highlighted his favorite drugstore chains, but this week he's highlighting the wholesale drug distribution stocks starting with Cardinal Health (CAH).
Cardinal is now a $29 billion company that provides drugs and other medical and surgical supplies. It derives 87% of its revenue from the pharmaceutical side of its business, thanks to a joint venture with CVS Health (CVS) last year. The company is also bolstering its surgical supply business by buying Cordis, the division of Johnson & Johnson (JNJ) that makes cardiovascular supplies like stents, for $1.94 billion.
Cramer said Cardinal is not the cheapest of the bunch and is therefor not his favorite, but it remains a steal trading at just 17.9 times earnings.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.